• Cardiff Lexington entered an LOI to acquire a multi-location musculoskeletal healthcare platform operating in multiple states.
• Purchase price consideration up to USD 104 million, including USD 30 million cash at closing and USD 10 million unsecured notes due in two years.
• Sellers would receive preferred equity valued to equal 35% of fully diluted equity post-closing, with potential conversion above USD 120 million valuation.
• Earnout of up to USD 12 million in common stock tied to EBITDA thresholds for 2027, 2028, 2029.
• Target closing date set for Nov. 16, 2026, subject to due diligence, financing, and definitive agreements.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardiff Lexington Corp. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202609240800ACCESSWRNAPR_____1225980) on September 24, 2026, and is solely responsible for the information contained therein.